Biotech News

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued

Related news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

Stock data

Close
5.94 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States